|
Role of Oncogenic Kinase Pim-1 in Prostate Cancer
|
2R01CA123484-06A1
|
$280,943
|
$70,236
|
Abdulkadir, Sarki
|
VANDERBILT UNIVERSITY MED CTR
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-10
|
$13,680
|
$1,915
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Participation in the Eastern Cooperative Oncology Group
|
7U10CA107868-11
|
$160,010
|
$22,401
|
AISNER, JOSEPH
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
PARP Inhibition to Treat Triple-Negative Breast Cancer Brain Metastases
|
5K23CA157728-03
|
$173,089
|
$86,545
|
Anders, Carey
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
SPORE in Breast Cancer
|
2P50CA098131-11
|
$2,150,500
|
$537,625
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MED CTR
|
|
Image-guided combination therapy: noninvasive assessment of delivery and response
|
5R01CA154738-03
|
$550,456
|
$275,228
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-27
|
$1,874,946
|
$187,495
|
Atkins, James
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Explosive Evolution Under Stress: The Driving Forces of Cancer Dynamics (Main)
|
5U54CA143803-05
|
$2,479,751
|
$322,368
|
Austin, Robert
|
PRINCETON UNIVERSITY
|
|
Eastern Cooperative Oncology Group Studies
|
3U10CA014548-38S1
|
$334,918
|
$46,889
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
ENGINEERED INTELLIGENT MICELLE FOR TUMOR pH TARGETING
|
5R01CA101850-09
|
$247,262
|
$247,262
|
Bae, You
|
UNIVERSITY OF UTAH
|
|
San Juan Minority-Based Community Clinical Oncology Program
|
2U10CA052667-23
|
$573,647
|
$74,574
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-16
|
$320,126
|
$38,415
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-14S1
|
$31,250
|
$1,875
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-14
|
$2,082,690
|
$124,961
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
Clinical Studies to Circumvent Drug Resistance
|
ZIA BC 010620
|
$85,879
|
$8,588
|
Bates, Susan
|
CCR (NCI)
|
|
Novel deregulated genes in the etiology and progression of human prostate cancer
|
3R01CA138791-04S1
|
$44,583
|
$44,583
|
Batra, Surinder
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Novel deregulated genes in the etiology and progression of human prostate cancer
|
5R01CA138791-04
|
$336,747
|
$336,747
|
Batra, Surinder
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-29
|
$1,065,000
|
$181,050
|
Bearden, James
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
Cancer Center Support Grant
|
3P30CA042014-24S1
|
$43,750
|
$438
|
Beckerle, Mary
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
5P30CA042014-24
|
$1,433,304
|
$14,333
|
Beckerle, Mary
|
UNIVERSITY OF UTAH
|
|
Iowa Oncology Research Association
|
5U10CA035101-28
|
$747,553
|
$82,231
|
Behrens, Robert
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
ECOG Clinical Trials
|
5U10CA017145-38
|
$362,638
|
$50,769
|
BENSON, AL
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA022453-31S1
|
$12,500
|
$250
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA022453-31S2
|
$50,000
|
$1,000
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA022453-31
|
$2,376,242
|
$47,525
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
Hawaii Minority-Based Clinical Community Oncology Program
|
5U10CA063844-20
|
$736,823
|
$73,682
|
Berenberg, Jeffrey
|
UNIVERSITY OF HAWAII AT MANOA
|
|
Eastern Cooperative Oncology Group
|
5U10CA049957-25
|
$291,047
|
$40,747
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY MED CTR
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-28S1
|
$362,418
|
$21,745
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-32
|
$9,816,255
|
$1,177,951
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-29
|
$2,684,982
|
$161,099
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Southwest Oncology Group Treatment Grant
|
3U10CA032102-34S1
|
$429,287
|
$77,272
|
BLANKE, CHARLES
|
UNIVERSITY OF MICHIGAN
|
|
Southwest Oncology Group Treatment Grant
|
5U10CA032102-34
|
$12,219,352
|
$2,199,483
|
BLANKE, CHARLES
|
UNIVERSITY OF MICHIGAN
|
|
SWOG Community Clinical Oncology Program Research Base
|
7U10CA037429-29
|
$4,229,363
|
$380,643
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
GYNECOLOGIC ONCOLOGY GROUP STATISTICAL AND DATA CENTER
|
5U10CA037517-29
|
$4,168,555
|
$3,668,328
|
BLESSING, JOHN
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Cancer and Leukemia Group B - The Ohio State University
|
5U10CA077658-16
|
$447,372
|
$53,685
|
BLOOMFIELD, CLARA
|
OHIO STATE UNIVERSITY
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-10
|
$262,036
|
$131,018
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy
|
ZIA SC 006353
|
$821,808
|
$123,271
|
Brechbiel, Martin
|
CCR (NCI)
|
|
Community Clinical Oncology Program
|
5U10CA037422-26
|
$2,811,894
|
$84,357
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Eastern Cooperative Oncology Group
|
3U10CA080775-14S1
|
$43,980
|
$6,157
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
North Central Cancer Treatment Group
|
3U10CA025224-33S1
|
$5,872,026
|
$587,203
|
BUCKNER, JAN
|
MAYO CLINIC ROCHESTER
|
|
Cancer and Leukemia Group B
|
5U10CA032291-32
|
$454,439
|
$54,533
|
Burstein, Harold
|
DANA-FARBER CANCER INST
|
|
Ozark Health Ventures, LLC dba Cancer Research for the Ozarks
|
5U10CA045560-25
|
$744,590
|
$126,580
|
Carlson, Jay
|
OZARK HEALTH VENTURES, LLC
|
|
Bcl-2 Proteins in Mechanism of Anti-mitotic Drug Action
|
5R01CA109821-09
|
$213,574
|
$106,787
|
CHAMBERS, TIMOTHY
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Tumor-targeted Polymersomes to image and Treat Ovarian Cancer
|
1R01CA175480-01A1
|
$342,934
|
$171,467
|
Cheng, Zhiliang
|
UNIVERSITY OF PENNSYLVANIA
|
|
Cancer and Leukemia Group B
|
3U10CA077597-14S2
|
$85,066
|
$10,208
|
CHESON, BRUCE
|
GEORGETOWN UNIVERSITY
|
|
SPORE in Prostate Cancer
|
3P50CA069568-15S1
|
$560,104
|
$56,010
|
CHINNAIYAN, ARUL
|
UNIVERSITY OF MICHIGAN
|
|
Minimal Residual Disease and Mechanisms of Breast Cancer Recurrence
|
5R01CA143296-04
|
$302,718
|
$30,272
|
CHODOSH, LEWIS
|
UNIVERSITY OF PENNSYLVANIA
|
|
In Vivo Cancer Therapy Monitoring with Diffuse Optical Methods
|
5R00CA126187-05
|
$227,037
|
$22,704
|
CHOE, REGINE
|
UNIVERSITY OF ROCHESTER
|
|
Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas
|
1R41CA165318-01A1
|
$300,000
|
$75,000
|
Christensen, Dale
|
ONCOTIDE PHARMACEUTICALS, INC.
|
|
Targeted Docetaxel-Nanocolloid for the Treatment of Ovarian Cancer
|
1U43CA162454-01A1
|
$288,302
|
$288,302
|
Coleman, Timothy
|
NEMUCORE MEDICAL INNOVATIONS, INC.
|
Total relevant funding to Taxol for this search: $53,683,024
|